Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome
Go back to Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 22.52 +0.43 (1.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.09 | 52 Week High | $42.49 | |||
| Open | $22.26 | 52 Week Low | $16.64 | |||
| Day High | $22.66 | P/E | N/A | |||
| Day Low | $22.01 | EPS | $-0.42 | |||
| Volume | 352,434 | |||||
